{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-foot/prescribing-information/oral-griseofulvin/","result":{"pageContext":{"chapter":{"id":"4f73cab3-f311-54bd-beac-8bb860f26e2f","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin","depth":2,"htmlHeader":"<!-- begin field 360b8d42-60b4-42f7-963f-a8d200c55859 --><h2>Oral griseofulvin</h2><!-- end field 360b8d42-60b4-42f7-963f-a8d200c55859 -->","summary":"","htmlStringContent":"<!-- begin item 7f629c7f-4438-41b0-a93f-a8d200c55397 --><!-- end item 7f629c7f-4438-41b0-a93f-a8d200c55397 -->","topic":{"id":"32650c82-f347-5933-adc6-d0da00f3d764","topicId":"35b0fa0c-8988-453f-af54-60cd595d29ad","topicName":"Fungal skin infection - foot","slug":"fungal-skin-infection-foot","lastRevised":"Last revised in April 2018","chapters":[{"id":"66fe4516-176d-5ffc-aebd-99a58afbd57c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5231c18b-820c-586e-87f0-5527574f70d1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e2b3169b-582d-5dda-b94f-73ccd139eede","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e1fd155-8f48-5bf7-a40c-4d2931a41736","slug":"changes","fullItemName":"Changes"},{"id":"8249fd1f-7c27-535b-a721-9e280d761ea5","slug":"update","fullItemName":"Update"}]},{"id":"e4ea5f16-99ef-5247-87e9-141b06d8b21a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"524d92eb-2792-5543-a6d9-78e4f825cf22","slug":"goals","fullItemName":"Goals"},{"id":"a678e6e3-5a4b-55cb-b7d6-c6ab9580eda2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"44708a93-b41d-5827-9293-650b191df0b0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d578224-3b80-58f6-9894-5c90e41c1b44","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a029f7b6-3344-51e6-ab22-bafdf196a4b7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b487a461-1526-54bb-a2df-4e2e0562293d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0e034d35-5e8d-5db3-a518-77103caa73c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"73e18fb0-6f03-51ed-bddf-355959375e75","slug":"definition","fullItemName":"Definition"},{"id":"a33dea25-362f-5128-9c14-d178ef837bfe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"a4167228-e44b-560b-8406-20294a5b8e42","slug":"prevalence","fullItemName":"Prevalence"},{"id":"91f3fb6f-6926-547c-830c-dd963749fb55","slug":"complications","fullItemName":"Complications"},{"id":"8373f46b-763e-53e3-9ea8-90cd767d66e6","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"090da929-a640-586e-a803-a47b38656e1d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"024c307f-3650-539d-b0b4-4f1c4a8db49e","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e3544fc8-cba9-524d-aed2-f28ae6f802e8","slug":"assessment","fullItemName":"Assessment"},{"id":"3ad14837-2b4c-58ab-b5c5-456d63d403ae","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"db051fa9-f61e-5787-bd5d-b2ff4a77ba85","fullItemName":"Management","slug":"management","subChapters":[{"id":"a11a4a32-6cc1-5c40-8396-099a218e1487","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d96bb08c-b21d-517b-830e-ead35a26fe8e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"27a2a883-b20f-5b25-825b-3bc5b02c1f77","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"476702d7-9e1a-5dfd-b3b0-899ebce5130b","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"e3c1f25f-1a76-53af-aef4-b39eecdf04d7","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"4f73cab3-f311-54bd-beac-8bb860f26e2f","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"aaec6565-5327-5bd4-bc06-a1442065c1bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c64c0494-1e71-5960-a8c9-a05141d2801c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"265ba112-5e5e-59c8-8569-29d1a263263d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e7088451-abf0-5e2f-a546-109de8062cbf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"96559e5f-dca9-5c90-af8c-c1182e5d3306","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd075cd9-9444-5680-bd23-a168ebe2b5a2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"49b473c6-a745-5480-9602-1224549611f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"65b0f432-1967-593c-a9f7-2326776f4e83","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d96bb08c-b21d-517b-830e-ead35a26fe8e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"0318eb39-74b6-5743-a5c8-b7d9e7a2d68c","slug":"dosing-schedule","fullItemName":"Dosing schedule","depth":3,"htmlHeader":"<!-- begin field 1dfe5901-0ab4-4077-b6ab-a8d200dff3d5 --><h3>Dosing schedule</h3><!-- end field 1dfe5901-0ab4-4077-b6ab-a8d200dff3d5 -->","summary":"","htmlStringContent":"<!-- begin item f2f22b4f-6d8f-417b-9001-a8d200dfee74 --><!-- begin field 553bbdc3-4848-40c5-aed4-a8d200dff3d5 --><ul><li>For adults, prescribe griseofulvin 500 mg daily, increased if necessary to 1000 mg daily for severe infections, for at least four weeks; reduce the dose when treatment response occurs.<ul><li>The daily dose may be taken once daily or in divided doses. Treatment should be continued for at least two weeks after lesions have healed.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 553bbdc3-4848-40c5-aed4-a8d200dff3d5 --><!-- end item f2f22b4f-6d8f-417b-9001-a8d200dfee74 -->","subChapters":[]},{"id":"6d3c5c91-dc10-597b-830e-31daabd960c5","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 4d16c6b6-9929-441e-b139-a8d200c57d30 --><h3>Contraindications and cautions</h3><!-- end field 4d16c6b6-9929-441e-b139-a8d200c57d30 -->","summary":"","htmlStringContent":"<!-- begin item 24373fdc-26ec-463a-b416-a8d200c57b1f --><!-- begin field 51678e30-a01d-44b5-a55a-a8d200c57d30 --><ul><li><strong>Do not prescribe griseofulvin to people with:</strong><ul><li>Acute porphyria.</li><li>Severe liver disease.</li><li>Systemic lupus erythematosus — increased risk of exacerbation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 51678e30-a01d-44b5-a55a-a8d200c57d30 --><!-- end item 24373fdc-26ec-463a-b416-a8d200c57b1f -->","subChapters":[]},{"id":"7a02ce81-ce62-509d-805f-3196a3764ed2","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field f5011a3d-43f1-46bd-ab1c-a8d200c5a0ea --><h3>Adverse effects</h3><!-- end field f5011a3d-43f1-46bd-ab1c-a8d200c5a0ea -->","summary":"","htmlStringContent":"<!-- begin item b4a6a644-f7c7-42c5-b61d-a8d200c59cf5 --><!-- begin field 61d3b4aa-e4d1-4aa3-92e7-a8d200c5a0ea --><ul><li><strong>Possible adverse effects of griseofulvin include:</strong><ul><li>Gastrointestinal — such as nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, anorexia.<ul><li>Advise the person to take griseofulvin after a high-fat meal to increase systemic absorption and reduce the risk of adverse effects.</li></ul></li><li>Hepatobiliary — alteration in liver function tests (LFTs), intrahepatic cholestasis, and hepatitis.</li><li>Neuropsychiatric — headache, dizziness, confusion, taste disturbance, impaired co-ordination and hearing<strong>, </strong>peripheral neuropathy, sleep disturbances, agitation, and irritability.<ul><li>Advise the person that griseofulvin may enhance the effects of alcohol and impair the performance of skilled tasks, such as driving.</li></ul></li><li>Skin — rashes such as erythema multiforme, toxic epidermal necrolysis, photosensitivity, bullous reactions (including Lyell's syndrome), urticarial reactions.</li><li>Other — fatigue, leucopenia, neutropenia, anaemia (usually resolve on stopping treatment).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 61d3b4aa-e4d1-4aa3-92e7-a8d200c5a0ea --><!-- end item b4a6a644-f7c7-42c5-b61d-a8d200c59cf5 -->","subChapters":[]},{"id":"db9d6808-22d2-5cf4-b574-8c1a81bafe46","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 47470a70-0746-4d17-9b63-a8d200c5be4a --><h3>Drug interactions</h3><!-- end field 47470a70-0746-4d17-9b63-a8d200c5be4a -->","summary":"","htmlStringContent":"<!-- begin item e469c0c5-7970-4823-80d5-a8d200c5bceb --><!-- begin field 2659068b-ae0b-4a6d-b656-a8d200c5be4a --><p><strong>Possible drug interactions with griseofulvin include:</strong></p><ul><li>Alcohol — concurrent use of alcohol and griseofulvin may cause a disulfiram-like reaction (flushing, tachycardia). Warn people about the possibility of this reaction.</li><li>Oral contraceptives — the efficacy of oral contraceptives may be reduced with concurrent griseofulvin use. The clinical significance of this effect is unknown.<ul><li>The Faculty of Sexual and Reproductive Healthcare (FSRH) recommends avoiding use of combined oral contraceptives (COCs) and progestogen-only contraceptives (POPs), the progestogen-only implant, and ulipristal acetate, and using an alternative method of contraception when using griseofulvin, and within 28 days of stopping treatment.<ul><li>If a woman wishes to use the COC when taking griseofulvin, consider an increased ethinylestradiol dose (at least 50 micrograms) during treatment and for a further 28 days after stopping griseofulvin, with a continuous or tricycling regimen plus pill-free interval of four days.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a>  for more information.</li></ul></li></ul></li><li>Warfarin — griseofulvin potentially decreases the efficacy of warfarin. Monitor the international normalized ratio (INR), and adjust the anticoagulant dose accordingly. </li><li>Phenobarbital — may result in a decreased plasma level of griseofulvin, leading to a reduction in efficacy.</li><li>Primidone — may result in a decreased plasma level of griseofulvin, leading to a reduction in efficacy.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 2659068b-ae0b-4a6d-b656-a8d200c5be4a --><!-- end item e469c0c5-7970-4823-80d5-a8d200c5bceb -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}